BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported third-quarter financial results.
BioCryst reported third-quarter revenue of $75.8 million, which beat average analyst estimates of $75.23 million, according to Benzinga Pro. $66 million came from ORLADEYO, the company's once-daily treatment for prevention of Hereditary Angioedema attacks.
BioCryst reported a quarterly net loss of 23 cents per share, which beat average estimates for a loss of 28 cents per share.
"With the strong underlying growth fundamentals we continued to see from patients and physicians in the third quarter, and the further growth dynamics we expect to see in the fourth quarter, we are on track to more than double ORLADEYO revenue in 2022 compared to 2021," said Charlie Gayer, chief commercial officer of BioCryst.
BioCryst said it expects full-year revenue from ORLADEYO to be $255 million. The company now expects full-year operating costs to be between $365 million and $370 million.
BioCryst is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases.
BCRX Price Action: BioCryst has a 52-week high of $19.99 and a 52-week low of $7.61.
The stock was down 12.7% at $11.61 at time of publication, according to Benzinga Pro.
Photo: Konstantin Kolosov from Pixabay.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.